Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT06389552
Recruiting Observational

Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

NCT06389552 · tracked via the Priya Life Science South Korea tracker
Sponsor
HK inno.N Corporation
Phase
Observational
Started
2023-09-25
Last updated
2024-04-29

Condition(s) studied

Adjuvant Chemotherapy

Study summary

This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age over 19 at the time of obtaining the informed consent form * Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery * ECOG 0 or 1 * Scheduled to RO or R1 resection * Organ function capable of chemotherapy Exclusion Criteria: * FOLFIRINOX contraindications among the drug approval requirements * Palliative Therapy * Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX

Primary outcome measure(s)

  • Disease-free survival — Day 1 to Week 88
    Duration of survival before pancreatic cancer recurrence or death

Trial sites (1)

FacilityCityRegionStatus
Seoul ST. Mary's Hospital Seoul South Korea Recruiting

More HK inno.N Corporation trials in South Korea

A Study to Evaluate the Pharmacokinetics and Safety of IN-M00007 and IN-R00007 in Healthy Adult Volunteers Starting soon
To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adult Volunteers Active, not recruiting
An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients Recruiting
A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients Recruiting
Tegoprazan-Aspirin Drug Interaction in Healthy Adult Male Volunteers Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06389552 on ClinicalTrials.gov ↗ ← All trials in South Korea